The treatment of Still’s disease has advanced remarkably in the last few years, with interleukin 1(IL-1) inhibition representing an effective and safe treatment option in patients with persistent inflammation after adequate glucocorticoid (GC) treatment (1). Here, IL1B is linked to systemic-onset juvenile idiopathic arthritis.